Navigation Links
Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
Date:6/3/2009

COPENHAGEN, June 3 /PRNewswire/ -- Santaris Pharma and Copenhagen Institute of Technology, Aalborg University, Denmark, announced today that Director of microRNA, Santaris Pharma, Sakari Kauppinen, has been appointed Adjunct Professor in RNA Biology at Copenhagen Institute of Technology. The appointment has immediate effect and will last five years. Sakari Kauppinen, who will continue his in current role as Director of MicroRNA Research at Santaris Pharma, will give his inaugural lecture in August this year.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090420/344344 )

Sakari Kauppinen, Director of MicroRNA Research at Santaris Pharma said:

"I feel very honored to be appointed Adjunct Professor in RNA Biology at the Copenhagen Institute of Technology, Aalborg University. Close collaborations with academia are essential for Santaris Pharma's expanding microRNA therapeutics program, which aims at translating the basic knowledge about microRNAs in disease into development of novel medicines with the potential to improve human health. I am looking forward to interacting closely with Aalborg University, whose experience in working with the biotech industry is highly synergistic with our way of collaborating with academia."

Soren Tulstrup, CEO of Santaris Pharma said:

"We are thrilled that Sakari Kauppinen has received this important academic appointment. Sakari Kauppinen has helped bring Santaris Pharma to a leadership position worldwide within the exciting new scientific field of microRNA, and I am sure he will contribute significantly to the university in his future additional capacity as Adjunct Professor."

Lene Lange, Professor, Dr. Scient. Vice Dean for the Faculties of Engineering, Science and Medicine, Aalborg University said:

"Sakari Kauppinen is superbly qualified for the position as Adjunct Professor at Copenhagen Institute of Technology, Aalborg University. The decision was made based upon his groundbreaking work, his standing as an international leader in the microRNA field, his service to the scientific community, and his status as a valued and generous colleague. A close relationship with the knowledge intensive private industry is very important to Aalborg University, so the fact that Sakari Kauppinen can achieve this stature while working as a scientist in Santaris Pharma makes him a truly rare individual and even more valuable for Copenhagen Institute of Technology and Aalborg University. The university is fortunate to have Sakari Kauppinen as a member of the Faculties of Engineering, Science and Medicine."

http://www.santaris.com

Santaris Pharma (founded in 2003) is a privately held biopharmaceutical company developing new classes of RNA medicines targeting disease-related mRNAs and miRNAs based on its proprietary LNA chemistry. The Company's own research and development activities focus on microRNAs, infectious diseases and metabolic disorders. Santaris Pharma is leveraging its highly effective and efficient Drug Discovery Engine to generate lead LNA drug candidates against a broad array of disease targets selected by strategic partners. The Company and its corporate partners currently have four compounds in clinical development and a full pipeline in late preclinical development. Santaris Pharma has since its inception raised nearly $100 million through private financing and upfront payments.

    Contact

    For further information, please contact
    Randi Krogsgaard, Director, Corporate Communications
    Direct phone +45-4517-9879
    Cell: +45-20488384
    E-mail: rmk@santaris.com



'/>"/>
SOURCE Santaris Pharma A/S
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
2. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
3. 2009 Pharma ChemOutsourcing Show Attendance Up an Astounding 60% Despite Current Recession
4. Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
5. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
7. ViroPharma to Present at Two June Healthcare Conferences
8. Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
11. Pharmacyclics Files Registration Statement for Rights Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers ... 5000 and the 6000i models are higher end machines that use the more unconventional ... spectrophotometer’s light beam from the bottom of the cuvette holder. , FireflySci has ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... , June 23, 2016 Apellis ... Phase 1 clinical trials of its complement C3 ... single and multiple ascending dose studies designed to ... (PD) of subcutaneous injection in healthy adult volunteers. ... (SC) either as a single dose (ranging from ...
Breaking Biology Technology:
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):